Roble Belko & Company’s AbbVie ABBV Stock Holding History

Roble Belko & Company’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.2M	Buy	5,503 +3	+0.1%	+$665	0.15%	54
2025 Q4	$1.26M	Sell	5,500 -25	-0.5%	-$5.7K	0.16%	48
2025 Q3	$1.28M	Buy	5,525 +3	+0.1%	+$611	0.17%	46
2025 Q2	$1.02M	Buy	5,522 +4	+0.1%	+$743	0.15%	50
2025 Q1	$1.16M	Buy	5,518 +362	+7%	+$70.4K	0.18%	48
2024 Q4	$916K	Buy	5,156 +700	+16%	+$129K	0.15%	57
2024 Q3	$880K	Buy	4,456 +27	+0.6%	+$5.04K	0.14%	57
2024 Q2	$760K	Hold	4,429	–	–	0.13%	61
2024 Q1	$807K	Buy	4,429 +3,837	+648%	+$661K	0.14%	56
2023 Q4	$92K	Buy	592 +186	+46%	+$27.1K	0.02%	133
2023 Q3	$61K	Sell	406 -37	-8%	-$5.43K	0.01%	140
2023 Q2	$60K	Hold	443	–	–	0.01%	134
2023 Q1	$71K	Sell	443 -31	-7%	-$4.74K	0.01%	137
2022 Q4	$77K	Hold	474	–	–	0.02%	138
2022 Q3	$64K	Hold	474	–	–	0.02%	140
2022 Q2	$73K	Sell	474 -70	-13%	-$10.7K	0.02%	137
2022 Q1	$88K	Buy	544 +28	+5%	+$4.07K	0.02%	139
2021 Q4	$70K	Buy	516 +70	+16%	+$8.27K	0.01%	139
2021 Q3	$48K	Buy	446 +31	+7%	+$3.54K	0.01%	151
2021 Q2	$47K	Hold	415	–	–	0.01%	163
2021 Q1	$45K	Hold	415	–	–	0.01%	154
2020 Q4	$44K	Hold	415	–	–	0.01%	141
2020 Q3	$36K	Buy	415 +172	+71%	+$16.2K	0.01%	144
2020 Q2	$24K	Sell	243 -1,930	-89%	-$170K	0.01%	180
2020 Q1	$166K	Hold	2,173	–	–	0.05%	92
2019 Q4	$192K	Sell	2,173 -687	-24%	-$57K	0.05%	101
2019 Q3	$217K	Buy	2,860 +2,617	+1,077%	+$179K	0.06%	84
2019 Q2	$18K	Hold	243	–	–	0.01%	206
2019 Q1	$20K	Hold	243	–	–	0.01%	166
2018 Q4	$22K	Hold	243	–	–	0.01%	146
2018 Q3	$23K	Hold	243	–	–	0.01%	150
2018 Q2	$23K	Hold	243	–	–	0.01%	153
2018 Q1	$23K	Hold	243	–	–	0.01%	165
2017 Q4	$24K	Hold	243	–	–	0.01%	154
2017 Q3	$22K	Hold	243	–	–	0.01%	133
2017 Q2	$18K	Hold	243	–	–	0.01%	143
2017 Q1	$16K	Hold	243	–	–	0.01%	154
2016 Q4	$15K	Sell	243 -200	-45%	-$12.2K	0.01%	170
2016 Q3	$28K	Buy	443 +200	+82%	+$12.9K	0.02%	139
2016 Q2	$15K	Hold	243	–	–	0.01%	170
2016 Q1	$14K	Hold	243	–	–	0.01%	145
2015 Q4	$14K	Hold	243	–	–	0.01%	133
2015 Q3	$13K	Hold	243	–	–	0.01%	132
2015 Q2	$16K	Buy	+243	New	+$15.9K	0.01%	137

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Roble Belko & Company's ABBV Position: Q1 2026 in Review

Roble Belko & Company increased its AbbVie (ABBV) stake by 0.05% in Q1 2026, buying an estimated $665 and bringing the position to 5,503 shares worth $1.2M. The position accounts for 0.15% of the portfolio, ranked #54.

Roble Belko & Company first reported a position in ABBV in Q2 2015 and has held it in 44 quarters since. The position peaked at $1.28M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Roble Belko & Company held 5,503 shares of AbbVie worth $1.2M as of Q1 2026.
Roble Belko & Company bought 3 AbbVie shares in Q1 2026, an estimated $665.
AbbVie made up 0.15% of Roble Belko & Company's portfolio in Q1 2026, its #54 holding.
Roble Belko & Company first reported a position in AbbVie in Q2 2015 and has held it in 44 quarters since.
Roble Belko & Company's AbbVie position peaked at $1.28M in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Roble Belko & Company's 13F filing for Q1 2026, filed 16 Apr 2026.